论文部分内容阅读
目的:观察丹红注射液联合贝那普利治疗早期糖尿病肾病的临床疗效。方法:糖尿病合并尿微量白蛋白(MAU)阳性者78例,随机分为丹红注射液联合贝那普利组(观察组)39例,贝那普利组(对照组)39例。观察治疗4周后两组MAU、血β2微球蛋白(β2-MG)、尿β2-MG、尿N-乙酰-B-D氨基葡萄糖苷酶(NAGE)、AngⅡ变化。结果:观察组MAU、血β2-MG、尿β2-MG、尿NAGE、AngⅡ较对照组减少更为明显,分别为(89.23±44.51)mg/dvs(111.14±44.37)mg/d,(2.76±1.34)mg/dvs(3.48±1.07)mg/d,(152.33±6.50)mg/dvs(190.24±4.03)mg/d,(20.79±4.90)U/Lvs(23.72±4.52)U/L,(47.11±19.86)vs(55.71±4.94)ng/L,肾功能(肌酐)变化两组间差异无统计学意义。丹红注射液联合贝那普利对糖尿病患者血脂有明显效果。结论:丹红注射液联合贝那普利治疗糖尿病合并早期肾损害的临床疗效优于单纯使用贝那普利。
Objective: To observe the clinical effect of Danhong injection and benazepril in the treatment of early diabetic nephropathy. Methods: Seventy-eight patients with positive urine microalbuminuria (MAU) were randomly divided into Danhong injection combined with benazepril group (observation group) 39 cases and benazepril group (control group) 39 cases. The MAU, blood β2 microglobulin (β2-MG), urinary β2-MG, urine NAGE and AngⅡ were observed after 4 weeks of treatment. Results: The MAU, blood β2-MG, urinary β2-MG, urine NAGE and AngⅡ in the observation group decreased more significantly than those in the control group (89.23 ± 44.51 mg / d vs 111.14 ± 44.37 mg / d and 2.76 ± 1.34 mg / dvs (3.48 ± 1.07) mg / d, (152.33 ± 6.50) mg / dvs (190.24 ± 4.03) mg / d and (20.79 ± 4.90) U / Lvs (23.72 ± 4.52) U / ± 19.86 vs 55.71 ± 4.94 ng / L, respectively. There was no significant difference between the two groups in the changes of renal function (creatinine). Danhong injection combined with benazepril has obvious effect on the blood lipids in diabetic patients. Conclusion: Danhong injection combined with benazepril is superior to benazepril in the treatment of diabetic patients with early renal damage.